Article
PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.
Neoplasia (New York, N.Y.) - 1 Jun 2026
Lou Hong, Langan David, Syracuse Nick, Murphy Elisabeth A, Kim Sojung, Robinson Emma, Rossi Nicole M, Xie Yi, Tulsyan Sonam, Joe Tawnjerae, Rodriguez Isabel, Rao Nina, Oberley Matthew R, Oelke Mathias, Dean Michael
Abstract excerpt
Cervical cancer is largely driven by human papillomavirus (HPV) infection, yet clinically actionable molecular subtypes and effective targeted therapies remain limited. Here, we define biologically and clinically relevant subtypes and evaluate targeted therapeutic strategies. Analysis of public datasets, coupled with functional studies in cervical cancer cell lines and immune assays, identified three subtypes:...
Topics
Join the communities discussing this publication.